Open an account

Oncotelic Therapeutics

OTLC · OTC

$0.0176−$0.0009 (−4.86%)TodayMarket closed ·
Prev close $0.0185

About OTLC

Oncotelic Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of anti-vascular therapeutics for patients with cancer and sight-threatening eye diseases. The company is headquartered in Agoura Hills, California and currently employs 38 full-time employees. The firm has three primary drugs and AI technology programs: AL-101 - Intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson’s Disease (PD), erectile dysfunction (ED) and female sexual dysfunction (FSD); CA4P- a vascular disrupting agent (VDA) - in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma; Oxi4503- a second generation VDA - for the treatment of liquid tumors with focus on childhood leukemia; OT-101 - an antisense against TGF-b2-for the treatment of various cancers and for the treatment of various viruses, and Artemisinin-a natural derivative from an Asian herb Artemisia Annua.

Employees
38
Headquarters
Agoura Hills, California
Listed
Aug 26, 1993
Sector
Health Care
Industry
Biotechnology
Website
oncotelic.com

OTLC key statistics

Market cap
8.04M
Price-earnings ratio
0.03
Dividend yield
—
Average volume
500.60K
Volume
227.04K
Open price
$0.018
High today
$0.0185
Low today
$0.0169
52 Week high
$0.11
52 Week low
$0.015

Oncotelic Therapeutics (OTLC) at a glance

As of Oct 20, 2026, Oncotelic Therapeutics (OTLC) shares are priced at $0.0176, giving the company a market cap of 8.04M and a price-to-earnings ratio of 0.03.

Today the stock has traded between $0.0169 and $0.0185. The current price is 4.1% above the day's low and 4.9% below its high.

Volume so far is 227.04K shares, below the average of 500.60K shares a day.

Over the past year Oncotelic Therapeutics has ranged from $0.015 to $0.11, and now sits 3% of the way up that range.

Oncotelic Therapeutics met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q4 FY25 it reported $0.59 per share against an estimate of $0.00.

OTLC earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 8 quarters, by 0.0% on average.

  1. Q3 FY22: reported $0.00 per share against an estimate of $0.00
  2. Q4 FY22: reported -$0.0139 per share against an estimate of $0.00
  3. Q1 FY23: reported $0.00 per share against an estimate of $0.00
  4. Q2 FY23: reported -$0.02 per share against an estimate of $0.00
  5. Q3 FY23: reported $0.00 per share against an estimate of $0.00
  6. Q1 FY24: reported $0.00 per share against an estimate of $0.00
  7. Q3 FY25: reported $0.00 per share against an estimate of $0.00
  8. Q4 FY25: reported $0.59 per share against an estimate of $0.00

OTLC news

  • Press releaseGlobe Newswire

    NetworkNewsAudio Announces Audio Press Release (APR) Discussing the Exploration of Nanoparticle, Targeted Drug-Delivery Technologies

  • Press releaseGlobe Newswire

    Oncotelic Therapeutics Inc. (OTCQB: OTLC) Eyeing Nanotech-Driven Delivery Systems, Pharmacokinetic Optimization to Advance Existing Oncology Therapies

  • Press releaseGlobe Newswire

    Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion

  • Press releaseGlobe Newswire

    Oncotelic Therapeutics Inc. (OTCQB: OTLC) Advancing Proprietary Solutions Focused on Nanotechnology-Enabled Drug Delivery, AI-Enhanced Biomedical Infrastructure

  • Press releaseGlobe Newswire

    How Advanced Drug Delivery Could Improve Existing Cancer Treatments

  • Press releaseGlobe Newswire

    NetworkNews Audio Announces Audio Press Release (APR) Discussing Developing Technologies Designed to Bypass BBB Limitations

  • Press releaseGlobe Newswire

    Oncotelic Therapeutics Inc. (OTCQB: OTLC) Responds to BBB Challenge with Next-Gen Drug-Delivery Platform

  • Press releaseGlobe Newswire

    CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research

Similar companies

Companies in the same industry as Oncotelic Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.